 RED BANK, N.J., July 6, 2021 PRNewswire -- Provention Bio, Inc. Nasdaq: PRVB, a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the U.S. Food and Drug Administration FDA has issued a Complete Response Letter CRL for the Companys Biologics License Application BLA for teplizumab for the delay of clinical type 1 diabetes T1D in at-risk individuals. 